Edition:
United States

People: Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

89.12EUR
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
€89.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
424,832
52-wk High
€98.82
52-wk Low
€70.64

Abi-Saab, Walid 

Dr. Walid Abi-Saab, M.D. has been Member of the Executive Committee, Chief Medical Officer of Galapagos NV since March 2017. He drives the overall medical strategy of the Company and is responsible for late stage clinical development and operations, medical and regulatory affairs, and safety. Before, hebworked at Shire Pharmaceuticals where he held various clinical development leadership roles, most recently as Group Vice President, Global Clinical Development - Therapeutic Area Head, Gastro-intestinal, Endocrinology and Metabolism. Prior to that, he led clinical development activities at Novartis, Abbott Laboratories and Pfizer, addressing a wide range of therapeutic areas and leading teams throughout the clinical development process. Under his leadership, more than 30 molecules have advanced through clinical development leading to several approvals in the US, EU and Canada. Prior to his pharma roles, he was Assistant Professor of Psychiatry and Neurosurgery at Yale University Medical School, where he headed their Schizophrenia Research at the Clinical Neuroscience Research Unit and the Neurosurgery Epilepsy Microdialysis Research Program. Mr. Walid Abi-Saab holds an MD degree from Universite Saint Joseph in Beirut, Lebanon.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --